Health-Related Quality of Life After Stereotactic Body Radiation Therapy for Localized Prostate Cancer: Results From a Multi-institutional Consortium of Prospective Trials

• Published in: International journal of radiation oncology, biology, physics Vol. 87; no. 5; pp. 939 - 945
• Main Authors: King, Christopher R., PhD, MD, Collins, Sean, MD, Fuller, Donald, MD, Wang, Pin-Chieh, PhD, Kupelian, Patrick, MD, Steinberg, Michael, MD, Katz, Alan, MD, JD
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-12-2013
• Subjects: Aged; ANDROGENS; Benchmarking; CLINICAL TRIALS; Health Status; Hematology, Oncology and Palliative Medicine; Humans; Male; NEOPLASMS; Organs at Risk - radiation effects; Prospective Studies; PROSTATE; Prostatic Neoplasms - pathology; Prostatic Neoplasms - surgery; Quality of Life; Radiation Dosage; Radiology; RADIOLOGY AND NUCLEAR MEDICINE; Radiosurgery - adverse effects; RADIOTHERAPY; Radiotherapy, Image-Guided - methods; Recovery of Function; Rectum - radiation effects; Self Report; Sexuality - radiation effects; STANDARD OF LIVING; Time Factors; TOXICITY; Treatment Outcome; Urinary Bladder - radiation effects
• ISSN: 0360-3016; 1879-355X
• DOI: 10.1016/j.ijrobp.2013.08.019

Purpose To evaluate the early and late health-related quality of life (QOL) outcomes among prostate cancer patients following stereotactic body radiation therapy (SBRT). Methods and Materials Patient self-reported QOL was prospectively measured among 864 patients from phase 2 clinical trials of SBRT for localized prostate cancer. Data from the Expanded Prostate Cancer Index Composite (EPIC) instrument were obtained at baseline and at regular intervals up to 6 years. SBRT delivered a median dose of 36.25 Gy in 4 or 5 fractions. A short course of androgen deprivation therapy was given to 14% of patients. Results Median follow-up was 3 years and 194 patients remained evaluable at 5 years. A transient decline in the urinary and bowel domains was observed within the first 3 months after SBRT which returned to baseline status or better within 6 months and remained so beyond 5 years. The same pattern was observed among patients with good versus poor baseline function and was independent of the degree of early toxicities. Sexual QOL decline was predominantly observed within the first 9 months, a pattern not altered by the use of androgen deprivation therapy or patient age. Conclusion Long-term outcome demonstrates that prostate SBRT is well tolerated and has little lasting impact on health-related QOL. A transient and modest decline in urinary and bowel QOL during the first few months after SBRT quickly recovers to baseline levels. With a large number of patients evaluable up to 5 years following SBRT, it is unlikely that unexpected late adverse effects will manifest themselves.